title: Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
abstract: The chemokine stromal-derived factor-1alpha (SDF-1alpha) and its receptor CXCR4 are critically involved in directional migration and homing of plasma cells in multiple myeloma. Here, we show that the expression of SDF-1alpha and CXCR4 was significantly down-regulated in patients treated with thalidomide (n=10) as compared to newly diagnosed MM patients (n=31) and MM patients treated with other drugs (n=38). SDF-1 alpha and CXCR4 expression was also significantly decreased in a RPMI 8226 cell line treated with 10 and 20micromol/L of thalidomide. Our findings indicate that thalidomide therapy induces down-regulation of CXCR4 and its ligand SDF-1alpha in multiple myeloma.
authors.affiliation: Laboratory of Genetics and Molecular Hematology - LIM-31, Medical School, Universidade de São Paulo, USP, 05403-000 São Paulo, Brazil.
authors.forename: Adriana Morgan
authors.initials: AM
authors.lastname: Oliveira
authors.forename: Durvanei Augusto
authors.initials: DA
authors.lastname: Maria
authors.forename: Martin
authors.initials: M
authors.lastname: Metzger
authors.forename: Camila
authors.initials: C
authors.lastname: Linardi
authors.forename: Ricardo Rodrigues
authors.initials: RR
authors.lastname: Giorgi
authors.forename: Fernanda
authors.initials: F
authors.lastname: Moura
authors.forename: Gracia Aparecida
authors.initials: GA
authors.lastname: Martinez
authors.forename: Sérgio Paulo
authors.initials: SP
authors.lastname: Bydlowski
authors.forename: Estela Maria
authors.initials: EM
authors.lastname: Novak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D054377:Chemokine CXCL12 / Q000235:genetics / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013792:Thalidomide / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; D012333:RNA, Messenger; D019718:Receptors, CXCR4; D013792:Thalidomide